Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADA | P00813 | 9/20 | 0.71 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6134005 | 0.86 | ADA (0.54) | ADAMCL1 | |
| SCHEMBL5672318 | 0.84 | ADA (0.71) | ADAKDM4E | |
| SCHEMBL5671044 | 0.84 | ADA (0.64) | ADAKDM4EALDH1A1 | |
| SCHEMBL6168397 | 0.83 | ADA (1.00) | ADA | |
| SCHEMBL6172027 | 0.83 | ADA (1.00) | ADA | |
| SCHEMBL5671899 | 0.83 | ADA (0.72) | ADA | |
| SCHEMBL23752598 | 0.82 | ADA (1.00) | ADA | |
| SCHEMBL6133545 | 0.82 | ADA (1.00) | ADA | |
| SCHEMBL5671122 | 0.82 | ADA (0.70) | ADA | |
| SCHEMBL6174229 | 0.82 | ADA (0.88) | ADA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6908940-B2 | Imidazole compounds and their use as adenosine deaminase inhibitors | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-06-21 | — | — | US | claimed |
| US-20040097571-A1 | Imidazole compounds and their use as adenosine deaminase inhibitors | ASTELLAS PHARMA INC. (JP) | 2004-05-20 | — | — | US | claimed |
| US-6908940-B2 | Imidazole compounds and their use as adenosine deaminase inhibitors | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-06-21 | — | — | US | disclosed |
| US-20040097571-A1 | Imidazole compounds and their use as adenosine deaminase inhibitors | ASTELLAS PHARMA INC. (JP) | 2004-05-20 | — | — | US | disclosed |
| EP-1261589-A1 | IMIDAZOLE COMPOUNDS AND THEIR USE AS ADENOSINE DEAMINASE INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-12-04 | — | — | EP | disclosed |
| WO-2001053271-A1 | IMIDAZOLE COMPOUNDS AND THEIR USE AS ADENOSINE DEAMINASE INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097571-A1 | Imidazole compounds and their use as adenosine deaminase inhibitors | ADA, AMPD2, AMPD1 | ADA 1/4885MCL1 1137/4885KDM4E 1634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.